New Needle for Two-Needle Hemodialysis

NCT ID: NCT01416896

Last Updated: 2011-08-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our preliminary studies have demonstrated that an innovative new design of the hemodialysis venous needle (the needle that returns the cleaned blood from the hemodialysis filter to the patient) with three jets is superior to the standard venous needle because it decreases the velocity and turbulence of the blood when compared with the standard venous needle, it is more efficient in the removal of toxins from the blood, and it is safe and effective. More importantly, our preliminary studies suggested that the new needle causes less damage to the dialysis vascular access and to circulating blood cells and less inflammation and oxidative stress. These will decrease medical complications, the high cost of care and death in dialysis patients. The current study will corroborate the finding of previous studies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

New venous needle, the "BME needle"

Hemodialysis using the new venous needle, the "BME needle".

Group Type EXPERIMENTAL

Hemodialysis using a new venous needle, the "BME needle"

Intervention Type PROCEDURE

Hemodialysis using a new venous dialysis needle or the "BME needle"

Hemodialysis using a new venous needle, the "BME needle"

Intervention Type PROCEDURE

One hemodialysis using a new venous needle, the "BME needle"

Standard venous needle, the "standard needle"

One hemodialysis using the standard venous needle, the "standard needle" (device).

Group Type ACTIVE_COMPARATOR

Hemodialysis using the standard venous needle

Intervention Type PROCEDURE

Hemodialysis using the standard venous dialysis needle

Hemodialysis using the standard venous needle

Intervention Type PROCEDURE

One hemodialysis using the standard venous needle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hemodialysis using the standard venous needle

Hemodialysis using the standard venous dialysis needle

Intervention Type PROCEDURE

Hemodialysis using a new venous needle, the "BME needle"

Hemodialysis using a new venous dialysis needle or the "BME needle"

Intervention Type PROCEDURE

Hemodialysis using a new venous needle, the "BME needle"

One hemodialysis using a new venous needle, the "BME needle"

Intervention Type PROCEDURE

Hemodialysis using the standard venous needle

One hemodialysis using the standard venous needle

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

hemodialysis using the standard venous dialysis needle The "BME needle" is a newly designed venous dialysis needle.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria:(1) end stage renal disease receiving hemodialysis in an ambulatory outpatient dialysis facility (2) male or female, (3) ages 18-80, (4) arterio-venous graft or AV fistula as vascular access,

Exclusion Criteria:patients with fever, infection, inflammation or malignancy will be excluded
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

Sponsor Role collaborator

Biomedical Enterprises Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Biomedical Enterprises Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alfredo R Zarate, MD

Role: PRINCIPAL_INVESTIGATOR

Biomedical Enterprises Inc

Pedro A Jose, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Children National Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

DaVita K Street Dialysis Center

Washington D.C., District of Columbia, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pedro A Jose, MD, PhD

Role: CONTACT

202-476-5715

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pedro A Jose, MD, PhD

Role: primary

202-476-5715

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R44DK059062

Identifier Type: NIH

Identifier Source: secondary_id

View Link

BME-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.